Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
Endometrial cancer (EC) stands among the most common gynecological malignancies in developed countries and regions, with a notable trend toward younger age at onset. Correspondingly, the demand for fertility-sparing treatment (FST) has been increasingly prominent among young EC patients. High-potency progestogens remain the sole therapeutic option recommended by international guidelines for this patient population; however, approximately 30% of patients exhibit no response to such treatment.
The concept of EC molecular subtyping, proposed by The Cancer Genome Atlas (TCGA) in 2013, has revolut